SOUTH SAN FRANCISCO, CA--(Marketwire - August 25, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional interim results from an ongoing Phase IIa clinical trial of CK-1827452 are scheduled to be presented as a poster presentation at the European Society of Cardiology (ESC) Congress 2008, to be held August 30-September 3, 2008 at the Messe München GmbH in Munich, Germany. The trial is evaluating an intravenous formulation of CK-1827452, a novel cardiac myosin activator being developed for the potential treatment of patients with either acutely decompensated or chronic heart failure in stable heart failure patients.
